Insmed adds ex-Sanofi CEO Paul Hudson and Verily CFO Utpal Koppikar to board

INSMED Inc

Board appointed Paul Hudson and Utpal Koppikar as independent directors effective Oct 19, 2026; Hudson is Class II, Koppikar Class I, both up for election at the 2027 annual meeting.
Hudson was Sanofi CEO from September 2019 to February 2026 and CEO of Novartis Pharmaceuticals from 2016 to 2019; he joins the Compensation Committee.
Koppikar has been Verily Health CFO since April 2023, was EVP and CFO of Atara Biotherapeutics from 2018 to 2023, and sits on C4 Therapeutics' (CCCC) board; he joins the Audit Committee.
Each director gets a $65,000 annual retainer plus $12,500 for committee service, prorated, and RSUs worth about $585,000 vesting in three equal annual installments.
Insmed said there are no arrangements or Item 404(a) related-party transactions involving either new director; CEO Will Lewis called it a strengthened board at a pivotal time.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.